已收盘 12-12 16:00:00 美东时间
+0.020
+0.06%
Mizuho analyst Nitin Kumar maintains Delek US Hldgs (NYSE:DK) with a Outperform and raises the price target from $45 to $51.
12-12 20:49
今日重点评级关注:Oppenheimer:维持Olema Pharmaceuticals"跑赢大市"评级,目标价从22美元升至45美元;Bernstein:维持Atlassian"跑赢大市"评级,目标价从290美元升至304美元
11-19 11:01
花旗上调Bilibili目标价升至27美元; 摩根士丹利上调英伟达目标价升至220美元;Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Piper Sandler analyst Ryan Todd maintains Delek US Hldgs (NYSE:DK) with a Neutral and raises the price target from $39 to $47.
11-14 23:42
今日重点评级关注:Piper Sandler:维持MeiraGTx Hldgs"超配"评级,目标价从28美元升至30美元;RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从26美元升至32美元
11-12 11:43
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
11-11 10:49
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Delek业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **第三季度核心财务表现:** - **调整后每股收益(EPS)**:1.52美元(剔除SRE影响) - **调整后EBITDA**:约3.19亿美元(剔除SRE影响);总调整后EBITDA约7.6亿美元 - **净利润**:1.78亿美元(2.93美元/股) - **调整后净利润**:4.34亿美元(7.13美元/股) - **调整后炼油利润率**:6.886亿美元(包含SRE收益) - **经营现金流**:4400万美元;调整工作资本后为1.5亿美元 **分部门业绩:**
11-08 12:04
Delek US Holdings shares are trading higher after the company reported better-t...
11-07 21:42
Delek US Hldgs (NYSE:DK) reported quarterly sales of $2.887 billion which beat the analyst consensus estimate of $2.763 billion by 4.49 percent. This is a 5.10 percent decrease over sales of $3.042 billion the same
11-07 19:36
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11